THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

Board Change

Alderley Park, 5 December 2023 - BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a differentiated approach to develop novel, next-generation anti-cancer precision Antibody Drug Conjugates, offering substantially improved cancer cell selectivity and therapeutic activity, announces that Non-Executive Director, Iain Ross, is stepping down from the board with immediate effect to pursue other interests.

During his time at BiVictriX, Iain Ross acted as Chairman and oversaw the Company's successful IPO in 2021 and its growth from Proof-of-Concept, toward nominating a clinical candidate for the first programme BVX001.  He moved to Non-Executive Director on 6 January 2023, where he offered the Company his continued support as it developed its lead assets within the Antibody Drug Conjugate space. 

A Nomination Committee, consisting of Non-Executive Directors and chaired by Dr. Michael Kauffman, will initiate a search for Iain's replacement with appropriate skills to help move the Company forward, in anticipation of its first clinical trials in patients with Acute Myeloid Leukaemia.

Dr Michael Kauffman, Chairman of BiVictriX, said: "On behalf of the Board, I would like to thank Iain for his contributions to BiVictriX over the last two years, and the Board would like to wish him all the very best for the future."

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed to selectively target cancer-specific antigen pairs, or "Bi-Cygni® fingerprints", on tumour cells, which are largely absent from healthy cells.

BiVictriX has established a growing proprietary library of cancer-specific Bi-Cygni® fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilises these novel Bi-Cygni® fingerprints, together with the Company's novel Antibody Drug Conjugate therapeutic design, to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.

Find out more about BiVictriX online at www.bivictrix.com